[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639116":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":37,"centralContacts":41,"locations":51,"responsibleParty":73,"collaborators":76,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":29,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":54,"whyStopped":29,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Gamma - Glutamylcystiene 400","EXPERIMENTAL","Each participant will receive gamma-glutamyl cysteine (GGC) capsules orally 400mg once a day for 3 months.",[13],"Drug: Gamma- Glutamylcysteine",{"label":15,"type":10,"description":16,"interventionNames":17},"Gamma - Glutamylcystiene 800","Each participant will receive gamma-glutamyl cysteine (GGC) capsules orally 400mg two times(morning-evening) a day for 3 months",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Gamma - Glutamylcystiene 1200","Each participant will receive gamma-glutamyl cysteine (GGC) capsules orally 400mg three times (morning-afternoon - evening) a day for 3 months",[22],"Drug: Gamma- Glutamylcusteine",[24,30,33],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Gamma- Glutamylcysteine","400mg capsules once a day",[9],null,{"type":25,"name":26,"description":31,"armGroupLabels":32,"otherNames":29},"400mg capsules orally (two times) per day",[15],{"type":25,"name":34,"description":35,"armGroupLabels":36,"otherNames":29},"Gamma- Glutamylcusteine","400mg capsules orally (three times) per day",[19],[38],{"name":39,"affiliation":5,"role":40},"Pravat Mandal, PhD","PRINCIPAL_INVESTIGATOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":29,"email":46},"Pravat Pravat K MANDAL","CONTACT","4126999561","mandalpk@pitt.edu",{"name":48,"role":44,"phone":49,"phoneExt":29,"email":50},"Nazia Pillar","878-670-3123","clinic55@pitt.edu",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"UPMC Presbyterian Hospital","RECRUITING","Pittsburgh","Pennsylvania","15213","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-79.99589,40.44062,{"lat":64,"lon":63},[67,69,70],{"name":68,"role":44,"phone":45,"phoneExt":29,"email":46},"Pravat Mandal",{"name":48,"role":44,"phone":29,"phoneExt":29,"email":50},{"name":71,"role":72,"phone":29,"phoneExt":29,"email":29},"Riddhi Patira, MD","SUB_INVESTIGATOR",{"type":74,"investigatorFullName":68,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"SPONSOR_INVESTIGATOR","Research Professor",[77,80],{"name":78,"class":79},"Robert J. Coury Family - Mylan Foundation","UNKNOWN",{"name":81,"class":79},"Inid Research Lab","100639116","phase-1-safety-and-tolerability-of-gamma-glutamylcysteine-ggc-oral-supplementation-in-mci-patients-100639116",false,"NCT07583251","Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients","Study For Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients","MCI-GSH","Inclusion Criteria:\n\n1. Memory complaints;\n2. MCI diagnosis\n3. MoCA score between 18-25\n4. Age 55 - 80 years old.\n5. Ability to read and write in English\n\nExclusion Criteria:\n\n1. Subjects with acute head trauma or head injury involving loss of consciousness;\n2. Subjects with a history of cancer;\n3. Subjects with a history of schizophrenia, manic-depressive disorder\n4. Subjects on antioxidant therapy (ashwagandha, gingko biloba, N-acetylcysteine or glutathione)\n5. Subjects on illicit drug (cocaine, heroin, marijuana, or fentanyl) abuse\u002Fdependence;","ALL","55 Years","80 Years",{"count":94,"type":95},9,"ESTIMATED","INTERVENTIONAL",[98],"PHASE1","The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg\u002Fday or 800mg\u002Fday or 1200mg\u002Fday) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.",[101],"Mild Cognitive Impairment (MCI)",[103,104,105,106],"GSH","GGC","MCI","cognitive","2026-05-29",{"date":109,"type":110},"2026-06-03","ACTUAL",{"date":112,"type":95},"2026-06",{"date":114,"type":95},"2027-02",{"name":68,"class":6},1]